IsoPlexis Completes $25 Million Series C Financing

By on , In the News

BRANFORD, Conn., May 14, 2019/PRNewswire/ — IsoPlexis, a company focused on advancing single-cell biomarkers to address critical challenges in oncology & beyond, today announced that it had raised $25 million in Series C funding. The round was led by Northpond Ventures and included new strategic investment along with current investors Spring Mountain Capital, Ironwood Capital, North Sound Capital, and […]

Ironwood Capital Connecticut Portfolio Company IsoPlexis: Response noted in non-Hodgkin patients

By on , In the News

Reprinted from BioCT, June 22, 2018 IsoPlexis has announced the publication of clinical data demonstrating a significant association between the functionality of anti-CD19 CAR-T cell product before treatment, as defined by IsoPlexis’ Polyfunctional Strength Index (PSI), and the objective response in patients with non-Hodgkin lymphoma. “We were excited to collaborate on this groundbreaking research,” said […]

Ironwood Capital Connecticut Announces Investment in IsoPlexis

By on , Announcements

AVON, CONNECTICUT, November 28, 2016 – Ironwood Capital Connecticut, a unit of Ironwood Capital, is pleased to announce an investment in IsoPlexis, a venture capital funded life sciences company developing a diagnostic platform to measure cellular immune response in patients. “IsoPlexis has developed a broad platform with enormous potential to advance personalized medicine and has […]